Search
for

    Learn

    5 / 801 results

    Research

    5 / 271 results

    Community Join

    5 / 1000+ results

      community Androgenic alopecia exclusively on the vertex of the scalp

      in Chat  6 upvotes 2 years ago
      A user experienced androgenic alopecia starting at the vertex without frontal hairline recession and is seeking information on this pattern. Another user noted that vertex or diffuse hair loss is common among men.

      community My skin is always dry and flakes like chalk (25)

      in Transgender  6 upvotes 2 years ago
      The user underwent a biopsy two years ago and was diagnosed with keratosis pilaris, leading to hair issues. They tried treatments including Minoxidil, betamethasone, lymecycline, topical Accutane, and dutasteride, as well as diet changes, without improvement in hair thickness or skin dryness.

      community can someone help me identify these pls

      in Treatment 6 months ago
      The user is experiencing diffuse thinning and inflammation despite using 2.5mg dutasteride daily, ciclopirox, and ketoconazole shampoos. They are considering treatments like hydroxychloroquine and JAK inhibitors due to suspected scarring alopecia and have faced challenges in obtaining a scalp biopsy.

      community Injured temple with derma rolling

      in Microneedling  2 upvotes 1 year ago
      OP injured their temple using derma rolling and tretinoin, causing peeling and potential hair follicle damage. Users suggest the injury might be permanent, possibly resulting in scar tissue where hair won't grow.

      community EMA is re-examining Winlevi (clascoterone at lower concentration)

      in Treatment  8 upvotes 11 months ago
      Clascoterone in Winlevi, a topical AR antagonist, is being re-examined due to concerns about HPA axis suppression in adolescents, but it's unlikely to be banned for adult use in androgenetic alopecia (AGA). The European Medicines Agency recommended refusing Winlevi for acne vulgaris, but this may not affect Breezula's approval for AGA.